Asialaw 2022 Rankings


Once again, the Firm is placed in Tier 1 for IP and Pharma & Lifesciences close

Remfry & Sagar has once again been recognised as ‘Outstanding’ for ‘Intellectual Property’ in the Asialaw 2022 Rankings. It is also placed in the top tier for ‘Pharmaceuticals and Life Sciences’.

In addition, Ashwin Julka (Managing Partner) has been recognised as an ‘Elite Practitioner’, Ranjna Mehta-Dutt (Partner – Patents) as a ‘Distinguished Practitioner’ and C.A. Brijesh (Partner – IP Litigation) as a ‘Notable Practitioner’.





As per the rules of the Bar Council of India, we are not permitted to solicit work or advertise in any manner. By proceeding further and clicking on “I Agree” below, the user acknowledges that the transmission, receipt or use of the information on our website does not tantamount to solicitation, advertisement, inducement or personal communication of any sort for and on behalf of the Firm so as to create an attorney-client relationship.

The information provided herein should not be interpreted as legal advice, for which the user must make independent inquiries. Whilst every effort has been taken to ensure the accuracy of the contents of this website, Remfry & Sagar disclaims all liability arising from reliance placed by the user or any other third party on the information contained therein.